FATE Fate Therapeutics Inc

Price (delayed)

$89.75

Market cap

$8.44B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.12

Enterprise value

$8.43B

Highlights
The company's equity has surged by 106% QoQ
FATE's revenue is up by 27% since the previous quarter
The company's quick ratio rose by 46% QoQ but it fell by 2.1% YoY
The net income has plunged by 65% YoY and by 7% from the previous quarter
The debt rose by 46% year-on-year and by 14% since the previous quarter

Key stats

What are the main financial stats of FATE
Market
Shares outstanding
94.04M
Market cap
$8.44B
Enterprise value
$8.43B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.65
Price to sales (P/S)
209.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
210.4
Earnings
Revenue
$40.06M
EBIT
-$184.96M
EBITDA
-$181.62M
Free cash flow
-$47.5M
Per share
EPS
-$2.12
Free cash flow per share
-$0.51
Book value per share
$8.42
Revenue per share
$0.43
TBVPS
$11.19
Balance sheet
Total assets
$1.05B
Total liabilities
$255.87M
Debt
$110.92M
Equity
$790.1M
Working capital
$709.74M
Liquidity
Debt to equity
0.14
Current ratio
8.5
Quick ratio
8.59
Net debt/EBITDA
0.06
Margins
EBITDA margin
-453.3%
Gross margin
100%
Net margin
-461.7%
Operating margin
-349%
Efficiency
Return on assets
-25.1%
Return on equity
-35.7%
Return on invested capital
-38.4%
Return on capital employed
-19.4%
Return on sales
-461.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FATE stock price

How has the Fate Therapeutics stock price performed over time
Intraday
1.5%
1 week
23.3%
1 month
15.06%
1 year
200.67%
YTD
-1.3%
QTD
8.85%

Financial performance

How have Fate Therapeutics's revenue and profit performed over time
Revenue
$40.06M
Gross profit
$40.06M
Operating income
-$139.8M
Net income
-$184.96M
Gross margin
100%
Net margin
-461.7%
The operating margin has soared by 68% YoY and by 14% from the previous quarter
The net income has plunged by 65% YoY and by 7% from the previous quarter
The net margin has surged by 56% year-on-year and by 16% since the previous quarter
FATE's revenue is up by 27% since the previous quarter

Growth

What is Fate Therapeutics's growth rate over time

Valuation

What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
10.65
P/S
209.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
210.4
FATE's EPS is down by 34% year-on-year
The company's equity has surged by 106% QoQ
FATE's price to book (P/B) is 66% higher than its 5-year quarterly average of 6.4 but 4.1% lower than its last 4 quarters average of 11.1
The stock's price to sales (P/S) is 72% more than its 5-year quarterly average of 121.7
FATE's revenue is up by 27% since the previous quarter

Efficiency

How efficient is Fate Therapeutics business performance
FATE's return on sales has surged by 56% year-on-year and by 16% since the previous quarter
The ROIC has grown by 39% YoY and by 30% from the previous quarter
Fate Therapeutics's return on assets has increased by 35% YoY and by 20% QoQ
The ROE has grown by 31% YoY and by 23% from the previous quarter

Dividends

What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FATE.

Financial health

How did Fate Therapeutics financials performed over time
The total liabilities has soared by 149% YoY and by 8% from the previous quarter
FATE's total assets has surged by 68% since the previous quarter
The debt is 86% smaller than the equity
The company's equity has surged by 106% QoQ
The company's debt to equity has shrunk by 60% YoY and by 44% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.